Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hematology

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,735 result(s) found for: Hematology. Displaying page 1 of 87.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2014-005189-31 Sponsor Protocol Number: 181114 Start Date*: 2014-12-16
    Sponsor Name:Dept Hematology SLB Vejle [...]
    1. Dept Hematology SLB Vejle
    2. Dept Hematology SLB Vejle
    Full Title: “Monoclonal antibodies for treatment of multiple myeloma. Present status and aspects of effector mechanisms with emphasis on the CD38 antibody daratumumab ”.
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10028567 Myeloma, malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001614-94 Sponsor Protocol Number: 15-PP-03 Start Date*: 2015-07-03
    Sponsor Name:Centre Hospitalier Universitaire de Nice
    Full Title: Hepatoprotective role of SMOFlipid® used in short-term parenteral nutrition in an Onco-Hematology Pediatric Population, pilot study
    Medical condition: parenteral nutrition in an Onco-Hematology Pediatric Population
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004865 10065877 Dietary and nutritional therapies HLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000302-10 Sponsor Protocol Number: UHKT-COVID19 Start Date*: 2022-01-24
    Sponsor Name:Institute of hematology and blood transfusion
    Full Title: Significance of T cell response to vaccination against SARS-CoV2 for leukemic patients with weakend immune system
    Medical condition: Recipients of cell therapy (allo HSCT, CAR19 T cells) indicated to vaccination against COVID19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002085-12 Sponsor Protocol Number: S54252 Start Date*: 2012-06-11
    Sponsor Name:University Hospitals Leuven
    Full Title: Pharmacokinetic evaluation of the voriconazole IV to oral switch
    Medical condition: Adult and pediatric hematology patients treated with intravenous voriconazole to cure an invasive fungal infection, and ready to switch from intravenous to oral administration of voriconazole
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10042941 Systemic fungal infection NOS LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001724-34 Sponsor Protocol Number: PS0020 Start Date*: 2021-03-02
    Sponsor Name:UCB Biopharma SRL
    Full Title: A Multicenter, Open-Label, Randomized Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA DE (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005688-18 Sponsor Protocol Number: Paw1 Start Date*: 2016-05-25
    Sponsor Name:Department of Hematology, Aalborg University Hospital
    Full Title: A randomized controlled trial of alendronate as preventive treatment against the development of gluco-corticoid-induced osteoporosis in patients being treated for malignant lymphoma
    Medical condition: Age ≥ 18 years. Patients with new diagnosis or recurrence of lymphoma, which is expected to be treated with one of the listed chemotherapy regimens. Expected lifespan ≥2 years
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10025315 Lymphoma malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-002667-14 Sponsor Protocol Number: UHKT-RLP/2011 Start Date*: 2011-07-19
    Sponsor Name:Institute of Hematology and Blood Transfusion
    Full Title: Effect of vaccination in patients with recurrent respiratory papillomatosis– can we improve the quality of life of these patients?
    Medical condition: Recurrent respiratory papillomatosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023849 Laryngeal papilloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2013-003403-19 Sponsor Protocol Number: HCK1 Start Date*: 2013-09-25
    Sponsor Name:Karolinska University Hospital
    Full Title: Study of T- and B-cell immunity after vaccination with a virosomebased influenza vaccine (Inflexal V) in patients who have undergone hematopoietic allogeneic stem cell transplantation.
    Medical condition: Allogeneic stem cell transplantation
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004869-14 Sponsor Protocol Number: CLL19H1 Start Date*: 2019-04-15
    Sponsor Name:Dept. of hematology, Herlev Hospital
    Full Title: Peptide vaccination with PD-L1 and PD-L2 peptides in untreated chronic lymphatic leukemia.
    Medical condition: Chronic lymphocytic leukemia with un-mutated IGHV
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-003990-93 Sponsor Protocol Number: MY18H2 Start Date*: 2018-12-12
    Sponsor Name:Department of Hematology, Herlev and Gentofte University Hospital
    Full Title: Phase IIa trial of PD-L1 peptide vaccination as monotherapy in high risk smoldering multiple myeloma
    Medical condition: High risk smoldering multiple myeloma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10075894 Smoldering myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-004526-41 Sponsor Protocol Number: ONCOGHdC2015-02 Start Date*: 2017-03-23
    Sponsor Name:Grand hôpital de Charleroi
    Full Title: A PHASE Ib/II STUDY TO EVALUATE SAFETY AND EFFICACY OF ATEZOLIZUMAB COMBINED WITH RADIO-CHEMOTHERAPY IN A PREOPERATIVE SETTING FOR PATIENTS WITH LOCALIZED RECTAL CANCER (R-IMMUNE)
    Medical condition: Rectum cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003809-22 Sponsor Protocol Number: MDS Start Date*: 2022-09-09
    Sponsor Name:Karolinska University Hospital
    Full Title: A phase II multicenter single-armed study using subject-specific minimal residual disease markers to adopt treatment after allogeneic stem cell transplantation for subjects with myelodysplastic syn...
    Medical condition: Myelodysplastic syndrome (MDS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003789-15 Sponsor Protocol Number: NMSG#20/13 Start Date*: 2014-01-08
    Sponsor Name:Nordic Myeloma Study Group
    Full Title: Phase II study of carfilzomib- cyclophosphamide-dexamethasone and high-dose melphalan followed by randomization between observa-tion or maintenance with carfil-zomib and dexamethasone in pa-tients ...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10067095 Multiple myeloma progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) FI (Completed) SE (Completed) NO (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2022-000478-25 Sponsor Protocol Number: MK-7962-008 Start Date*: 2023-02-20
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sotatercept (MK-7962) in Children from 1 to Less Than 18 Years of Age With PAH on Standard...
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10037403 Pulmonary hypertension NOS LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002425-30 Sponsor Protocol Number: 0171 Start Date*: 2020-03-17
    Sponsor Name:Theravance Biopharma Ireland Limited
    Full Title: A Phase 3, 182-week, Open-Label, Extension Study to Investigate the Safety and Tolerability Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension (symptomatic nOH) in Subjects...
    Medical condition: Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) ES (Prematurely Ended) PL (Completed) EE (Completed) FR (Completed) PT (Prematurely Ended) AT (Prematurely Ended) BG (Prematurely Ended) DE (Prematurely Ended) HU (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002034-47 Sponsor Protocol Number: AF219-014 Start Date*: 2015-10-12
    Sponsor Name:Afferent Pharmaceuticals, Inc.
    Full Title: A Study to Assess the Effect of AF-219 on Cough Reflex Sensitivity in Both Healthy and Chronic Cough Subjects
    Medical condition: Chronic cough
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-000734-35 Sponsor Protocol Number: TV48125-CNS-10141 Start Date*: 2019-07-25
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Single-Dose, Open-Label Study to Characterize the Pharmacokinetics, Safety and Tolerability of Subcutaneous administration of Fremanezumab in Pediatric Migraine Patients (6 to 11 Years of Age ...
    Medical condition: Prevention of migraine
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-004192-41 Sponsor Protocol Number: A0221109 Start Date*: 2020-09-03
    Sponsor Name:Pfizer
    Full Title: LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY OF FESOTERODINE IN JAPANESE PEDIATRIC SUBJECTS WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED WITH A NEUROLOGICAL CONDITION (NEUROGENIC DETRUSOR ...
    Medical condition: Urinary Bladder, Neurogenic
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-000672-28 Sponsor Protocol Number: VX10-770-107 Start Date*: 2017-03-27
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2, Single-Blind, Placebo-Controlled Study to Evaluate the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis, the G551D Mutation, and FE...
    Medical condition: cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-000299-40 Sponsor Protocol Number: CRAD001C2121 Start Date*: 2016-05-12
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, open label, two-way crossover study investigating the relative bioavailability of a single 5 mg dose of everolimus administered as either 5x1 mg everolimus intact tablets or 5x1 mg ev...
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 08 12:07:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA